This study is looking at adults with moderate-to-severe plaque psoriasis. It's testing a treatment plan that includes ILUMYA (an injection that targets IL-23, a protein involved in psoriasis) and, for some, HALOG Ointment 0.1%. You would receive ILUMYA injections at weeks 0, 4, and 16. If your body surface area (BSA, the amount of skin affected by psoriasis) is still more than 3% at week 16, you would also use HALOG Ointment for 4 weeks. The main goal is to see how much your BSA improves by week 16. The study plans to enroll 25 participants, but its current status is unclear.

Study design

This is an interventional study involving 25 adult participants. It is not specified if it is randomized or blinded.

What's involved

You would receive ILUMYA injections at weeks 0, 4, and 16. If needed, you would apply HALOG Ointment twice daily for 4 weeks starting at week 16. You would be evaluated at weeks 20 and 24.

Compensation

Not stated in the trial record.

Follow-up

Participants will be evaluated at weeks 20 and 24, following treatment that begins at week 0 and potentially includes ointment application up to week 20.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.